Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.88M Buy
78,083
+2,008
+3% +$52.5K 0.51% 41
2026
Q1
$2.14M Buy
76,075
+3,959
+5% +$105K 0.76% 27
2025
Q4
$1.8M Sell
72,116
-8,339
-10% -$210K 0.56% 32
2025
Q3
$2.05M Buy
80,455
+9,322
+13% +$230K 0.66% 30
2025
Q2
$1.72M Buy
71,133
+5,572
+8% +$130K 0.65% 32
2025
Q1
$1.66M Buy
65,561
+8,073
+14% +$211K 0.7% 29
2024
Q4
$1.53M Sell
57,488
-8,634
-13% -$234K 0.54% 39
2024
Q3
$1.91M Sell
66,122
-2,952
-4% -$86.1K 0.67% 30
2024
Q2
$1.93M Buy
69,074
+18,436
+36% +$508K 0.7% 26
2024
Q1
$1.41M Sell
50,638
-6,683
-12% -$185K 0.52% 43
2023
Q4
$1.65M Buy
57,321
+828
+1% +$25K 0.62% 32
2023
Q3
$1.87M Buy
56,493
+3,663
+7% +$130K 0.93% 16
2023
Q2
$1.94M Sell
52,830
-74
-0.1% -$2.88K 0.85% 15
2023
Q1
$2.16M Sell
52,904
-989
-2% -$42.7K 1.11% 15
2022
Q4
$2.76M Sell
53,893
-20,233
-27% -$970K 1.58% 11
2022
Q3
$3.24M Buy
74,126
+546
+0.7% +$26.5K 1.98% 10
2022
Q2
$3.86M Buy
73,580
+3,198
+5% +$163K 2.32% 9
2022
Q1
$3.64M Buy
70,382
+964
+1% +$50K 1.7% 13
2021
Q4
$4.1M Buy
+69,418
New +$3.44M 1.7% 12

Other funds holding PFE

Wealth Effects's PFE Position: Q2 2026 in Review

Wealth Effects increased its Pfizer (PFE) stake by 2.6% in Q2 2026, buying an estimated $52.5K and bringing the position to 78,083 shares worth $1.88M. The position accounts for 0.51% of the portfolio, ranked #41.

Wealth Effects first reported a position in PFE in Q4 2021 and has held it in 19 quarters since. The position peaked at $4.1M in Q4 2021. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Wealth Effects held 78,083 shares of Pfizer worth $1.88M as of Q2 2026.
  • Wealth Effects bought 2,008 Pfizer shares in Q2 2026, an estimated $52.5K.
  • Pfizer made up 0.51% of Wealth Effects's portfolio in Q2 2026, its #41 holding.
  • Wealth Effects first reported a position in Pfizer in Q4 2021 and has held it in 19 quarters since.
  • Wealth Effects's Pfizer position peaked at $4.1M in Q4 2021.
  • 2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Wealth Effects's 13F filing for Q2 2026, filed 6 Aug 2026.